Active — Not RecruitingNot Applicable

Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders

United States111 participantsStarted 2025-07-16

Plain-language summary

The goal of this study is to reduce Anticholinergic Medication (ACM) in persons with psychoses or serious mental illness, when these medications are no longer needed.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. are 18 years or older
✓. have a chart DSM V diagnosis of schizophrenia spectrum or schizoaffective or bipolar disorder or any other mental illness disorder
✓. have received ACM and antipsychotic medications for 6 months or more
✓. are considered to be clinically stable (by the patient's healthcare team) for 3 months or more
✓. the ACM (e.g. benztropine and/or trihexyphenidyl) is being used to treat EPS associated with antipsychotic medications.
✓. on an examination using the modified Simpson-Angus Extrapyramidal Symptoms Scale (head dropping and leg pendulousness items are dropped), no single item rated at 3 or 4.
✓. able and willing to sign the approved informed consent document.

Exclusion criteria

✕. patients with ongoing Parkinsonian symptoms who require ACM meds for countering EPS side effects based on the Simpson-Angus Scale score cutoffs.
✕. if the clinicians treating the potentially eligible patients consider them to be clinically unstable or if drug-addiction is the focus of treatment and participation in ACM de-prescription protocols is considered risky, the team will defer to the treating clinicians to exclude participants.
✕. The same exclusions will apply to those persons undergoing medical procedures and treatments that make participation in this ACM deprescription trial unwise per the treating team.

What they're measuring

Reduction of Anticholinergic Medications

Timeframe: From enrollment to final visit. The final visit can vary for each participant and can be up to 16 weeks following the first baseline visit.

Trial details

NCT IDNCT07043803

SponsorUniversity of Pittsburgh

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-05

View on ClinicalTrials.gov More Schizophenia Disorder trials